Canada · Delayed Price · Currency is CAD Theralase Technologies Company Description
Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research, development, and commercialization of energy activated small molecules and associated drug formulations in Canada, the United States, and internationally.
The company operates in two segments, Drug Division and Device Division. It engages in the research and development of Rutherrin, an injectable form of Ruvidar for the treatment of glio blastoma multiforme, a form of brain cancer, non-small cell lung cancer, pancreatic cancer, colorectal cancer, and muscle invasive bladder cancer; and Ruvidar, a topical treatment for herpes simplex virus-1 lesions and an extracorporeal treatment for lymphoma, leukemia, and multiple myeloma.
The company also researches, develops, manufactures, and distributes Cool Laser Therapy systems to healthcare practitioners for the healing of pain.
Theralase Technologies Inc. is based in Toronto, Canada.
| Country | Canada |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 20 |
| CEO | Roger Dumoulin-White |
Contact Details
Address: 41 Hollinger Road Toronto, ON M4B 3G4 Canada | |
| Phone | 416 699 5273 |
| Website | theralase.com |
Stock Details
| Ticker Symbol | TLT |
| Exchange | TSX Venture Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CAD |
| ISIN Number | CA88337V1004 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Roger John Dumoulin-White B.Sc., P.Eng. | President, Chief Executive Officer and Chairman |
| Kristina Hachey CPA | Chief Financial Officer and Director |
| Dr. Arkady Mandel DSc., M.D., Ph.D. | Chief Scientific Officer and Director |
| David M. Groves B.A | President of World Trade Division |
| Dr. Terry Ruch DVM | Equine Medical Consultant |